Reina Haque to Chemoradiotherapy
This is a "connection" page, showing publications Reina Haque has written about Chemoradiotherapy.
Connection Strength
0.950
-
Utilization of extended-interval, fixed-dosing of durvalumab, every 4?weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation. Future Oncol. 2026 Jan; 22(1):115-121.
Score: 0.950